RESUMEN
BACKGROUND: Chronic inflammatory diseases lead to glycation of protein, lipids and nuclear acids. One product generated in this context is pentosidine. AIM: To study pentosidine levels in Systemic Lupus Erythematosus (SLE) and its possible association with disease activity and cumulative damage. METHODS: Pentosidine serum levels were measured in the serum by ELISA commercial kits in 79 patients with SLE. Disease activity index and cumulative damage were studied by SELENA-SLEDAI (Safety of Estrogen in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index) and cumulative damage by SLICC/ACR DI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for Systemic Lupus Erythematosus) respectively and simultaneously with determination of pentosidine levels. Epidemiological and clinical and serological profile were collected from the charts. RESULTS: In the 79 studied patients, the SLEDAI ranged from 0 to 12 (median of 0) and the SLICC/ACR-DI from 0 to 4 (median of 0). Serum pentosidine levels did not correlate with SLEDAI neither with SLICC. Patients with discoid skin lesions and photosensitivity had lower levels than those without them, with p â= â0.04 in both. CONCLUSION: In SLE, serum pentosidine levels did not reflect activity and cumulative damage. Patients with skin manifestations had lower levels of this biomarker.
RESUMEN
Antitopoisomerase-1 (ou Scl-70) é um autoanticorpo considerado como biomarcador da forma difusa de esclerodermia. Alguns autores o têm encontrado em pacientes com lúpus. O objetivo deste estudo foi estudar a presença do anticorpo Scl-70 em lúpus eritematoso sistêmico (SLE). É pesquisa com 94 pacientes com LES para anticorpo anti Scl-70 usando o kit comercial de ELISA Virgo™, Columbia, USA. Dados clínicos, epidemiológicos e sorológicos foram obtidos dos prontuários. Como resultado, somente 2 pacientes (2.1%) tinham anticorpos anti Scl-70 em baixos títulos. Nenhum deles tinha características de esclerodermia. Em conclusão, não se confirmam achados anteriores acerca da presença de anti Scl-70 em lúpus. Este anticorpo parece ser específico para esclerodermia.
Antitopoisomerase-1 (or Scl-70) is an autoantibody considered as a biomarker of the diffuse form of scleroderma. Some authors have found it in lupus patients. The aim of this study was to study the presence of the Scl-70 antibody in systemic lupus erythematosus (SLE). It is screened with 94 SLE patients for anti Scl-70 antibody using the commercial Virgo™ ELISA kit, Columbia, USA. Clinical, epidemiological and serological data were obtained from medical records. As a result, only 2 patients (2.1%) had anti-Scl-70 antibodies at low titers. None of them had features of scleroderma. In conclusion, previous findings regarding the presence of anti Scl-70 in lupus are not confirmed. This antibody appears to be specific for scleroderma.
RESUMEN
OBJETIVO: Relatar o caso de um lactente de 5 meses com aparecimento espontâneo de equimoses cutâneas, com suspeita inicial de maus tratos e que revelou na evolução o diagnóstico de hemofilia B. RELATO DO CASO: aparecimento espontâneo de duas nodulações circundadas por porções arroxeadas da pele, uma em braço esquerdo e outra em dorso. O coagulograma mostrou um TAP de 13,4, um RNI de 1,26, um KPTT incoagulável e plaquetas de 643.000. Evoluiu com choque hipovolêmico por sangramento em partes moles, necessitando de transfusão de concentrado de hemácias. CONSIDERAÇÕES: As hemofilias são doenças relativamente raras, mas potencialmente graves e de alta morbidade devido suas complicações crônicas. O diagnóstico diferencial com maus tratos deve ser sempre investigado se houver suspeita clínica
OBJECTIVE: To report the case of a 5-month-old infant with spontaneous appearance of cutaneous ecchymosis, with initial suspicion of mistreatment and who revealed the diagnosis of hemophilia B in the evolution. CASE REPORT: spontaneous appearance of two nodulations surrounded by purple portions of the skin, one on the left arm and one on the back. The coagulogram showed a prothrombin time of 13.4, an INR of 1.26, an incoagulable APTT and platelets of 643,000. He evolved with hypovolemic shock due to soft tissue bleeding, requiring transfusion of red blood cell concentrate. CONSIDERATIONS: Hemophilia is a relatively rare disease, but potentially serious and of high morbidity due to its chronic complications. The differential diagnosis with maltreatment should always be investigated if there is clinical suspicion